OTC:CC - Ocumetics Completes One-Month Postoperative Examinations - Results Pending
(TheNewswire)
Calgary, Alberta – TheNewswire - September 16, 2025 -Ocumetics Technology Corp . (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advancedophthalmic technology, is excited to announce that it has completedone-month postoperative examinations of the first patients who wereimplanted with the Ocumetics Accommodating Intraocular Lens in MexicoCity on August 15, 2025 (the “Ocumetics Lens”).
“On Friday September 12 th , we performedone-month postoperative examinations of our first patients implantedwith the Ocumetics Lens,” said Dean Burns,President and CEO of Ocumetics Technology Corp. “During theexaminations we observed progress with recovery and completed a numberof visual acuity measurements. Our team will analyze patient clinicalreports early this week and provide an update shortly,” addsBurns.
The Company’s first-in-human clinical protocol wasstrategically designed to address three patient groups. The Company iscurrently proceeding with Group 1 patients. Surgeries for the secondand final day of Group 1 patients are scheduled for September 24,2025.
The endpoints for each group are focused on thefollowing key areas of evaluation:
Primary endpoints:
• Safety - establishing a clear baseline of patienthealth and recovery
• Distance vision correction - assessing theOcumetics Lens’s ability to restore far vision
Secondary endpoints:
• Product handling and surgical delivery - ensuringprocedural efficiency and reliability
• Near reading ability - evaluating the OcumeticsLen’s ability to restore close-range vision
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that is dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims totransform the field of ophthalmology with state-of-the-art intraocularlenses and other vision-enhancing technologies.
Ocumetics is in the preclinical study phase of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye, potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Corporation mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.
Copyright (c) 2025 TheNewswire - All rights reserved.